CD47 and neoplasm: Emerging combinations such as PD‐L1 × TGF‐β, PD‐1 × 4‐1BB, and CD47 × PD‐L1 illustrate opportunities to integrate immune modulation with tumor‐intrinsic pathway inhibition [21, 22].